Lee presents 18 patients who developed new symptoms at the spinal level adjacent to a prior lumbar fusion. The study defines the clinical and pathologic character of adjacent segment disease and the timeline over which it appears. No incidence rate is calculable, but the series establishes facet arthritis as the dominant pathology and provides the first detailed clinical description of this complication.
The longstanding assumption was that a short lumbar fusion (one or two levels) carries minimal long-term morbidity. This 1988 paper was among the first to document that the adjacent unfused segment pays a real clinical price — and that the price compounds with each extension.
When counseling a patient before lumbar fusion, this paper is why we discuss adjacent segment disease as a named long-term risk, not just a theoretical concern. The 5-year symptomatic rate should anchor your consent conversation, not the 8.5-year mean.
When a previously fused patient returns with new back or radicular symptoms, think facet arthritis at the adjacent level first. Not recurrent disc herniation. That distinction directs workup toward CT evaluation of facet hypertrophy and stenosis.
The finding that each fusion extension creates a new adjacent level at risk (with a third procedure needed in 4 of 9 extension cases after only 3 years) is the clinical argument for exhausting non-operative options and minimizing fusion levels whenever possible.
Lee presents 18 patients who developed new symptoms at the spinal level adjacent to a prior lumbar fusion. The study defines the clinical and pathologic character of adjacent segment disease and the timeline over which it appears. No incidence rate is calculable, but the series establishes facet arthritis as the dominant pathology and provides the first detailed clinical description of this complication.
The longstanding assumption was that a short lumbar fusion (one or two levels) carries minimal long-term morbidity. This 1988 paper was among the first to document that the adjacent unfused segment pays a real clinical price — and that the price compounds with each extension.
When counseling a patient before lumbar fusion, this paper is why we discuss adjacent segment disease as a named long-term risk, not just a theoretical concern. The 5-year symptomatic rate should anchor your consent conversation, not the 8.5-year mean.
When a previously fused patient returns with new back or radicular symptoms, think facet arthritis at the adjacent level first. Not recurrent disc herniation. That distinction directs workup toward CT evaluation of facet hypertrophy and stenosis.
The finding that each fusion extension creates a new adjacent level at risk (with a third procedure needed in 4 of 9 extension cases after only 3 years) is the clinical argument for exhausting non-operative options and minimizing fusion levels whenever possible.